Evidence map›Paper›PMID 32431536›Full record

ArticleJournal of pain research2020

Usefulness of a Double-Blind Placebo-Controlled Response Test to Demonstrate Rapid Onset Analgesia with Phenytoin 10% Cream in Polyneuropathy.

David J Kopsky, Alexander F J E Vrancken, Jan M Keppel Hesselink, Ruben P A van Eijk, Nicolette C Notermans

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04647877 (Enrichment Randomized Double-blind, Placebo-controlled Cross-over Trial With PHEnytoin Cream in Patients With Painful Chronic Idiopathic Axonal polyNEuropathy), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04647877 phase2 / phase3completednot on this map

Enrichment Randomized Double-blind, Placebo-controlled Cross-over Trial With PHEnytoin Cream in Patients With Painful Chronic Idiopathic Axonal polyNEuropathy

TypeinterventionalSponsorDavid J. KopskyRan2020 to 2023Enrolled81ConditionsChronic Idiopathic Axonal PolyneuropathyArmsphenytoin cream, Placebo cream
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Update on Toxic Neuropathies.Current treatment options in neurology · 2022
    Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

David J KopskyInstitute for Neuropathic Pain, Amsterdam, the Netherlands.ORCID 0000-0003-4820-489X
Alexander F J E VranckenDepartment of Neurology, Brain Centre University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0003-4649-6534
Jan M Keppel HesselinkInstitute for Neuropathic Pain, Bosch En Duin, the Netherlands.ORCID 0000-0002-0186-8050
Ruben P A van EijkDepartment of Neurology, Brain Centre University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-7132-5967
Nicolette C NotermansDepartment of Neurology, Brain Centre University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-9363-4103
Utrecht University · NLAmsterdam Institute for Addiction Research · NLJeroen Bosch Ziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTopical analgesics are an upcoming treatment option for neuropathic pain. In this observational study, we performed a double-blind placebo-controlled response test (DOBRET) in patients with polyneuropathy to determine the personalized analgesic effect of phenytoin 10% cream. PATIENTS AND

methodsIn a double-blind fashion, 12 consecutive adult patients with symmetrical painful polyneuropathy and equal pain intensity of ≥4 on the 11-point numerical rating scale (NRS) applied phenytoin10% cream on one painful area and a placebo cream on the corresponding contralateral area. We defined responders as patients who experienced a pain reduction ≥2 NRS points from baseline and ≥1 NRS point difference in pain reduction in favour of phenytoin 10% cream compared with placebo cream within 30 minutes after application. We also evaluated the percentage of pain reduction and frequency of 30% and 50% pain relief from baseline.

resultsSix patients (50%) were responders. Compared with placebo cream, pain reduction was higher in phenytoin 10% cream-applied areas with mean difference in pain reduction of 1.3 (95% CI: 1.1 to 1.8; p<0.001) on the NRS and mean percentage difference in pain reduction of 22% (95% CI: 13% to 32%; p =0.03). All responders had at least 30% pain reduction, and 4 out of 6 had at least 50% pain reduction in the phenytoin 10% cream applied area. All non-responders had less than 30% pain reduction. No side effects were reported.

conclusionA DOBRET is easy to perform, quickly identifies an analgesic effect in responders and could be a useful tool to personalize neuropathic pain treatment with topical formulations.

Indexed as

analgesicsneuropathic painneuropathytopical administrationtreatment

Identifiers

PMID32431536
PMCPMC7200258
OpenAlexW3021592882

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.